BioCentury
ARTICLE | Company News

Alethia, International Biotech Center (IBC) Generium deal

June 3, 2013 7:00 AM UTC

Alethia and IBC Generium partnered to co-develop Alethia's AB-16B5, an IgG2 mAb against clusterin (CLU; APOJ) in preclinical testing for cancer. Alethia will receive an upfront cash payment and R&D...